doi: 10.1016/s0305-7372(80)80025-9.
Mitotane (o,p'-DDD)
- PMID: 7397707
- DOI: 10.1016/s0305-7372(80)80025-9
Item in Clipboard
Mitotane (o,p'-DDD)
Cancer Treat Rev.
1980 Mar.
No abstract available
Similar articles
-
Mitotane use in inoperable adrenal cortical carcinoma.JAMA. 1973 Mar 5;223(10):1109-12. JAMA. 1973. PMID: 4739370 No abstract available.
-
Is there a role for low doses of mitotane (o,p'-DDD) as adjuvant therapy in adrenocortical carcinoma?J Clin Endocrinol Metab. 1998 Sep;83(9):3100-3. doi: 10.1210/jcem.83.9.5113. J Clin Endocrinol Metab. 1998. PMID: 9745410
-
o,p'-DDD (mitotane) therapy of adrenal cortical carcinoma: observations on drug dosage, toxicity, and steroid replacement.Cancer. 1978 Nov;42(5):2177-81. doi: 10.1002/1097-0142(197811)42:5<2177::aid-cncr2820420514>3.0.co;2-x. Cancer. 1978. PMID: 719602
-
Mitotane treatment for adrenocortical carcinoma: an overview.Minerva Endocrinol. 2012 Mar;37(1):9-23. Minerva Endocrinol. 2012. PMID: 22382612 Review.
-
[Diagnosis and treatment for adrenocortical carcinoma].Gan To Kagaku Ryoho. 2004 Mar;31(3):342-5. Gan To Kagaku Ryoho. 2004. PMID: 15045937 Review. Japanese.
Cited by
-
Adrenal cortical carcinoma.World J Surg. 2001 Jul;25(7):914-26. doi: 10.1007/s00268-001-0030-7. World J Surg. 2001. PMID: 11572033 Review.
-
Medical therapy of Cushing's disease.Pituitary. 2002;5(2):77-82. doi: 10.1023/a:1022308429992. Pituitary. 2002. PMID: 12675504 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
